CD30 is a cell surface antigen with low expression on normal activated lymphocytes but high expression on the surface of various lymphoma cells, so it has become one of the target antigens for lymphoma therapy. The antibody-binding drug brentuximab vedotin can be rapidly internalized into tumor cells to induce apoptosis after binding to CD30, and has a significant curative effect in clinical application. In addition, anti-CD30 chimeric antigen receptor-modified T cell therapy is safe, effective and well tolerated, bringing hope to patients with relapsed/refractory lymphoma. This article reviews the research progress of brentuximab vedotin and anti-CD30 chimeric antigen receptor-modified T cells in the treatment of lymphoma.